preclinical data
-
MP0726: Preclinical Data on Mesothelin-Targeting Radio-DARPin Presented by Molecular Partners and Orano Med at SNMMI 2025
Molecular Partners, in collaboration with Orano Med, is advancing its Radio-DARPin candidate, MP0726, which targets mesothelin (MSLN) for ovarian cancer treatment. Preclinical data reveals promising tumor accumulation and favorable biodistribution, including a high tumor-to-kidney ratio. The program leverages Molecular Partners’ Radio-DARPin platform, designed to improve the delivery of radioactive payloads to solid tumors. MP0726’s preclinical data is to be presented at the 2025 SNMMI Annual Meeting.
